STRATEGIC NEWS WATCH — July 30, 2026
|
Amgen’s Repatha won a positive EU opinion to prevent first heart attacks and strokes, headlining a session that also delivered an FDA panel’s rejection of Capricor’s Duchenne cell therapy, J&J’s $2.58 billion option on in vivo CAR-T maker Sail Biomedicines, and a Q2 earnings slate split between Regeneron’s record Dupixent quarter and a 29% slide in Alnylam. Today’s top developments:
|
What to Watch
- Capricor’s August 22 PDUFA — After the advisory committee voted against the DMD cell therapy on “fragile” data, watch whether the FDA issues a Complete Response Letter or demands confirmatory evidence; a rejection would raise the bar for cell therapies across small rare-disease populations.
- Repatha’s European Commission decision — A final EC verdict on the expanded primary-prevention indication is expected within months; clearance would open a large event-naive, high-risk population to PCSK9 therapy and pressure competitors to generate comparable first-event outcomes data.
- In vivo CAR-T consolidation — J&J’s $2.58 billion Sail option follows Lilly–Kelonia, AbbVie–Capstan and other deals; watch whether off-the-shelf, in-body engineering delivers durable clinical proof points to justify valuations now running ahead of the data.
- Second-half earnings divergence — Regeneron’s record Dupixent quarter against Alnylam’s guidance cut and BMS’s Cobenfy and milvexian delays sets up a bifurcated H2; watch which franchises convert beats into raised guidance versus which see launch curves and readouts slip.
- Sanofi’s late-stage clearout — With the Regeneron-partnered IL-33 candidate itepekimab terminated and a broad pipeline review underway, watch for further discontinuations or bolt-on licensing that signal where Sanofi expects its next growth drivers to originate.
This brief highlights the edition’s top stories. Read the full July 30, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.